Teva Pits Oral Laquinimod Against Avonex In MS Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
BRAVO trial is the second Phase III study underway for the novel oral drug.
You may also be interested in...
Biogen Idec Retains MS Focus, But It's "More Than Just Tysabri"
Biogen Idec made the case that it is a research-oriented biotech focused on home-grown therapeutic programs at the firm’s March 26 R&D day. It was an elaborately choreographed effort to remind investors that the firm is maintaining its focus on research and doesn’t plan to be a company that simply develops in-licensed products.
Biogen Idec Retains MS Focus, But It's "More Than Just Tysabri"
Biogen Idec made the case that it is a research-oriented biotech focused on home-grown therapeutic programs at the firm’s March 26 R&D day. It was an elaborately choreographed effort to remind investors that the firm is maintaining its focus on research and doesn’t plan to be a company that simply develops in-licensed products.
Infections, Death Fail To Stop Novartis’ Phase III MS Trial
“Confounding” factors in play; monitoring board gives green light to continue.